Ritholtz Wealth Management Biogen Inc. Transaction History

Ritholtz Wealth Management

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 18, 2023	SELL	$252.44 - $306.72 $292,325 - $355,181	-1,158 Reduced 61.5%	725 $0
Q3 2022 Oct 18, 2022	BUY	$194.69 - $268.46 $67,168 - $92,618	345 Added 22.43%	1,883 $503,000
Q2 2022 Jul 15, 2022	BUY	$187.54 - $223.02 $87,393 - $103,927	466 Added 43.47%	1,538 $314,000
Q1 2022 Apr 14, 2022	SELL	$193.77 - $244.14 $45,148 - $56,884	-233 Reduced 17.85%	1,072 $226,000
Q4 2021 Jan 18, 2022	SELL	$223.92 - $287.77 $209,589 - $269,352	-936 Reduced 41.77%	1,305 $313,000
Q3 2021 Oct 14, 2021	BUY	$282.99 - $369.05 $565 - $738	2 Added 0.09%	2,241 $634,000
Q2 2021 Jul 20, 2021	BUY	$259.0 - $414.71 $181,818 - $291,126	702 Added 45.67%	2,239 $775,000
Q1 2021 May 12, 2021	BUY	$242.95 - $284.63 $85,032 - $99,620	350 Added 29.49%	1,537 $430,000
Q4 2020 Jan 19, 2021	SELL	$236.26 - $355.63 $24,807 - $37,341	-105 Reduced 8.13%	1,187 $291,000
Q3 2020 Oct 23, 2020	BUY	$264.77 - $305.71 $139,004 - $160,497	525 Added 68.45%	1,292 $367,000
Q2 2020 Jul 15, 2020	BUY	$258.66 - $342.55 $198,392 - $262,735	767 New	767 $205,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Ritholtz Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Ritholtz Wealth Management with notifications on news.